CGTX vs CHRS

Cognition Therapeutics, Inc. vs Coherus Oncology, Inc. — Valuation Comparison 2026

CGTX

Biotechnology
Cognition Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
36
LOW
Price
$1.19
Last close
Models
6/13
Active
VS

CHRS

Biotechnology
Coherus Oncology, Inc.
Quality
6.8
out of 10
Value Trap
38
LOW
Price
$1.65
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType CGTX Fair ValueCGTX Upside CHRS Fair ValueCHRS Upside
Bayesian DCF Intrinsic $0.51 -57.3% $0.54 -67.0%
Earnings Power Value Intrinsic $9.90 +450.0%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.64 -45.8% $1.30 -21.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CGTX vs CHRS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CGTX vs CHRS — Which Stock Is More Undervalued?

CHRS scores higher with a 6.8/10 quality rating vs CGTX's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cognition Therapeutics, Inc. (CGTX) and Coherus Oncology, Inc. (CHRS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CGTX currently trades at $1.19 with a QOC of 4.1/10, while CHRS trades at $1.65 with a QOC of 6.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).